Johnson & Johnson to acquire Sail BiomedicinesJohnson & Johnson announced strategic agreements and a collaboration with Sail Biomedicines a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. "People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control," said John Reed, executive vice president, innovative medicine research & development, Johnson & Johnson. "Sail's innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way. By working together with Sail, we aim to accelerate the development of innovative therapies that have the potential to fundamentally transform how immune-mediated diseases are treated." Through this collaboration with GSK, we will generate novel datasets from physiologically relevant human disease systems that can help reveal important biological mechanisms and support future discovery efforts.